Lycia Therapeutics Launches U.S. IPO For Food Allergy, Graves' Disease Pipeline

Lycia Therapeutics, Inc. has filed an S‑1 registration statement to raise development capital through an initial public offering. The filing indicates the company plans to sell shares to investors to fund its research and development activities. The IPO is intended to provide the necessary funds for the company’s future growth and product development.

( LYCA ) has filed to raise development capital via an IPO, according to an S-1 registration statement . Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions.

Summarised by Agaah from Seeking Alpha. Agaah aggregates 36 sources and removes duplicate coverage — all news, one place.